Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 1/20 | 0.63 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | HDAC8 | Q9BY41 | 6/20 | 0.45 |
| ▸ | HDAC4 | P56524 | 4/20 | 0.45 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.43 |
| ▸ | RAD52 | P43351 | 1/20 | 0.43 |
| ▸ | UHRF1 | Q96T88 | 1/20 | 0.43 |
| ▸ | GPR6 | P46095 | 2/20 | 0.40 |
| ▸ | MAOA | P21397 | 1/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.39 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | GFER | P55789 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2714532 | 0.89 | IDO1 (0.51) | IDO1NPC1LMNAMEN1USP2 | |
| SCHEMBL30841489 | 0.89 | IDO1 (0.51) | IDO1NPC1LMNAMEN1USP2 | |
| Nitric Acid SCHEMBL11217579 | 0.88 | IDO1 (0.51) | IDO1NPC1LMNAMEN1USP2 | |
| Nitric Acid SCHEMBL11063338 | 0.79 | HDAC8 (0.43) | IDO1NPC1LMNAMEN1USP2 | |
| SCHEMBL11209768 | 0.77 | IDO1 (0.77) | IDO1LMNAMEN1USP2MAPT | |
| SCHEMBL95683 | 0.77 | IDO1 (1.00) | IDO1LMNAMEN1USP2MAPT | |
| SCHEMBL11210880 | 0.76 | IDO1 (0.56) | IDO1LMNAMEN1USP2MAPT | |
| SCHEMBL7379095 | 0.75 | NPC1 (0.45) | IDO1NPC1MEN1USP2KMT2A | |
| Bromide SCHEMBL11262736 | 0.75 | IDO1 (0.55) | IDO1LMNAMEN1USP2MAPT | |
| SCHEMBL11208941 | 0.74 | IDO1 (0.57) | IDO1NPC1LMNAMEN1USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2061450-B1 | METHODS OF MODULATING CELL PROLIFERATION AND CYST FORMATION IN POLYCYSTIC KIDNEY AND LIVER DISEASES | MEDICAL COLLEGE WISCONSIN INC (US) | 2017-04-19 | — | — | EP | claimed |
| US-7078400-B2 | 20-HETE synthase inhibitor | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2006-07-18 | — | — | US | claimed |
| EP-1226819-B1 | INHIBITOR FOR 20-HETE-YIELDING ENZYME | TAISHO PHARMACEUTICAL CO LTD (JP) | 2006-01-18 | — | — | EP | claimed |
| US-6864254-B1 | Inhibitor for 20-hete-yielding enzyme | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2005-03-08 | — | — | US | claimed |
| US-20040110830-A1 | 20-HETE synthase inhibitor | TAISHO PHARMACEUTICAL CO., LTD. | 2004-06-10 | — | — | US | claimed |
| EP-1226819-A1 | INHIBITOR FOR 20-HETE-YIELDING ENZYME | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2002-07-31 | — | — | EP | claimed |
| EP-0814806-A1 | USE OF FUSED BENZOTHIAZOLES AS NEUROPROTECTANTS | JANSSEN PHARMACEUTICA N.V. (BE) | 1998-01-07 | — | — | EP | claimed |
| WO-1996025931-A2 | USE OF FUSED BENZOTHIAZOLES AS NEUROPROTECTANTS | JANSSEN PHARMACEUTICA N.V. (BE) | 1996-08-29 | — | — | WO | claimed |
| EP-0021806-B1 | 2,3-DIHYDRO-IMIDAZO (2,1-B) BENZOTHIAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | JANSSEN PHARMACEUTICA N.V. (BE) | 1983-01-12 | — | — | EP | claimed |
| US-4364942-A | ANTIDEPRESSANTS, INHIBITORS OF MONOAMINE OXIDASE | JANSSEN PHARMACEUTICA N.V. (BE) | 1982-12-21 | — | — | US | claimed |
| US-4340738-A | ENZYME INHIBITORS, ANTIDEPRESSANTS | JANSSEN PHARMACEUTICA, N.V. (BE) | 1982-07-20 | — | — | US | claimed |
| US-4262004-A | MONOAMINE OXIDASE INHIBITORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 1981-04-14 | — | — | US | claimed |
| EP-0021806-A1 | 2,3-Dihydro-imidazo (2,1-b) benzothiazole derivatives and pharmaceutical compositions containing them | JANSSEN PHARMACEUTICA N.V. (BE) | 1981-01-07 | — | — | EP | claimed |
| EP-3098217-B1 | METHOD FOR PRODUCING OPTICALLY ACTIVE CARBOXYLIC ACID ESTER | UNIV TOKYO SCIENCE FOUND (JP) | 2018-04-25 | — | — | EP | disclosed |
| EP-2407447-B1 | METHOD FOR PRODUCING OPTICALLY ACTIVE 2-HYDROXY ESTER | TOKYO UNIV OF SCIENCE EDUCATIONAL FOUNDATION ADMINISTRATIVE ORGANIZATION (JP) | 2018-04-18 | — | — | EP | disclosed |
| EP-2061450-B1 | METHODS OF MODULATING CELL PROLIFERATION AND CYST FORMATION IN POLYCYSTIC KIDNEY AND LIVER DISEASES | MEDICAL COLLEGE WISCONSIN INC (US) | 2017-04-19 | — | — | EP | disclosed |
| US-4262004-A | MONOAMINE OXIDASE INHIBITORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 1981-04-14 | — | — | US | disclosed |
| US-4262004-A | MONOAMINE OXIDASE INHIBITORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 1981-04-14 | — | — | US | disclosed |
| EP-0021806-A1 | 2,3-Dihydro-imidazo (2,1-b) benzothiazole derivatives and pharmaceutical compositions containing them | JANSSEN PHARMACEUTICA N.V. (BE) | 1981-01-07 | — | — | EP | disclosed |
| EP-0021806-A1 | 2,3-Dihydro-imidazo (2,1-b) benzothiazole derivatives and pharmaceutical compositions containing them | JANSSEN PHARMACEUTICA N.V. (BE) | 1981-01-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110830-A1 | 20-HETE synthase inhibitor | ALOX5, ALOX15, ALOX15B | IDO1 782/4885NPC1 2423/4885LMNA 3962/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.